Skip to main content

Treatment of ANCA-associated systemic small-vessel vasculitis

Buy Article:

$43.00 plus tax (Refund Policy)

Jayne D. Treatment of ANCA-associated systemic small-vessel vasculitis. APMIS 2009; 117: 3–9.

Much has been learnt over the last 30 years to optimize the use of immunosuppressive and glucocorticoid therapies that has allowed the publication of treatment guidelines. However, major unmet needs remain in the treatment of ANCA-associated vasculitis (AAV) and include refractory disease, only partial efficacy and toxicity of current drugs and the need for long-term regimens. Newer therapies, including mycophenolate mofetil, leflunomide and rituximab, are providing a real opportunity for improved outcomes of AAV in the future. The development of therapy has been facilitated by international clinical research networks but delayed by the complexities of studying an uncommon, multi-system disease.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ANCA; Treatment; international research; small-vessel vasculitis

Document Type: Research Article

Affiliations: Renal Unit, Addenbrooke's Hospital, Cambridge, UK

Publication date: 01 June 2009

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more